Kimberly Song, MD

Thomas Marron, MD, PhD, is Assistant Director of Immunotherapy and Early Phase Trials at The Tisch Cancer Institute and Assistant Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. As a member of the Center for Thoracic Oncology, Dr. Marron treats thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, and malignant pleural mesothelioma. He leads numerous clinical trials for thoracic malignancies and hepatocellular carcinoma (liver cancer). He also leads the Phase 1 trials program at The Mount Sinai Hospital, where he enrolls patients into dozens of trials focused on development of novel cancer immunotherapies. As a member of The Tisch Cancer Institute and the Precision Immunology Institute, Dr. Marron works closely with basic scientists across the Mount Sinai Health System, translating preclinical findings into clinical advances. He leads a large translational neoadjuvant program focused on clinical trials for multiple types of cancer. The goal of these trials is to decrease the likelihood that cancer will return after surgery; in parallel, they support deep interrogation of the effect of new and standard therapies on the tumor immune microenvironment at the single-cell level. Further, the trials enable Dr. Marron and collaborators to define combination approaches that optimize response rates and the durability of novel immune-based therapies, while minimizing toxicity.

My clinical practice focuses exclusively on patients (both adult and pediatric) who undergo Bone Marrow Transplant (BMT) and overlaps with my clinical research. I have designed, conducted, analyzed, and authored multiple clinical trials and data analyses of clinical GVHD, specifically, and clinical BMT, broadly. My long term goal is to improve outcomes for patients who undergo BMT by designing and conducting high impact clinical trials. I co-direct the Mount Sinai Acute GVHD International Consortium [MAGIC] with James Ferrara, MD. This international consortium provides the opportunity to develop and test innovative treatment approaches for allogeneic BMT patient